MedTrace Logo

Pulse Versus Continuous Cyclophosphamide for Induction of Remission in ANCA-Associated Vasculitides

NCT00430105 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2007-02-01

No results posted yet for this study

Summary

A comparison of intermittent pulsed cyclophosphamide to daily oral cyclophosphamide for the treatment of ANCA-associated systemic vasculitides with kidney involvement.

Performed by the European Vasculitis Study group.

Conditions

  • ANCA Associated Systemic Vasculitis
  • Wegener's Granulomatosis
  • Microscopic Polyangiitis

Interventions

DRUG

cyclophosphamide

Sponsors & Collaborators

  • Cambridge University Hospitals NHS Foundation Trust

    lead OTHER

Principal Investigators

  • Kirsten de Groot · Klinikum Offenbach GmbH, Germany

  • Caroline OS Savage · University of Birmingham

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-02-28
Completion
2004-04-30

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00430105 on ClinicalTrials.gov